Lumosa Therapeutics Co (ROCO:6535) Net Change in Cash : NT$2.12 Mil (TTM As of Mar. 2025)

View and export this data going back to 2015. Start your Free Trial

What is Lumosa Therapeutics Co Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

Lumosa Therapeutics Co's Net Change in Cash for the three months ended in Mar. 2025 was NT$17.30 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was NT$2.12 Mil.

Lumosa Therapeutics Co Net Change in Cash Historical Data

The historical data trend for Lumosa Therapeutics Co's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lumosa Therapeutics Co Net Change in Cash Chart

Lumosa Therapeutics Co Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Net Change in Cash

Get a 7-Day Free Trial

729.83

-58.32

-323.47

-91.60

-189.76

Lumosa Therapeutics Co Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Change in Cash	Get a 7-Day Free Trial															-174.58	39.32	-52.79	-1.71	17.30

Lumosa Therapeutics Co Net Change in Cash Calculation

Lumosa Therapeutics Co's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash	=	Cash Flow from Operations	+	Cash Flow from Investing	+	Cash Flow from Financing	+	Effect of Exchange Rate Changes
	=	-296.326	+	-787.1	+	893.617	+	0.047
	=	-189.76

Lumosa Therapeutics Co's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash = Cash Flow from Operations + Cash Flow from Investing + Cash Flow from Financing + Effect of Exchange Rate Changes

= -81.044 + 100 + -1.684 + 0.028

= 17.30

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$2.12 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lumosa Therapeutics Co Net Change in Cash Related Terms
Thank you for viewing the detailed overview of Lumosa Therapeutics Co's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

Lumosa Therapeutics Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lumosa Therapeutics Co Ltd (ROCO:6535) » Definitions » Net Change in Cash

Comparable Companies

ROCO:4728 TPE:6550 ROCO:4743 ROCO:4147 ROCO:6589 ROCO:6547 ROCO:6712 ROCO:4162 ROCO:6617 TPE:6541 VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270

Traded in Other Exchanges

N/A

Address

Yuanyuan Street, 4th Floor, No. 3-2, Nangang District, Taipei, TWN, 11503

Website

https://www.lumosa.com.tw

Lumosa Therapeutics Co Ltd develops new drugs. The company is engaged in the development of drugs for unmet medical needs in the fields of CNS, oncology, and inflammatory diseases. Geographically, it derives a majority of its revenue from Asia and also has a presence in Taiwan, Europe, and America. Its product pipeline is Neuroscience which includes LT 1001 for Postoperative Pain, LT 3001 for Acute Ischemic Stroke, LT 5001 for Uremic Pruritus, LT 6001 for Neurological disorder, and Oncology including LT 2003 for Solid Tumor. It generates revenue from sales of goods.

Lumosa Therapeutics Co Headlines

No Headlines